Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Research Explores Whether Pro-, Pre- and Synbiotics Can Reduce the Risk of Colorectal Cancer - Nutraceuticals World
Research

Research Explores Whether Pro-, Pre- and Synbiotics Can Reduce the Risk of Colorectal Cancer

The SYNCAN project, an EU-sponsored multi-center European study coordinated by Orafti, aims to investigate whether pro-, pre- and synbiotics can reduce the risk of colorectal cancer, the most common form of cancer in the U.S. and EU. A key part of the project is a human volunteer study. The double-blind, placebo-controlled study involved 80 human volunteers, who had either intestinal polyps removed or had been treated for colon cancer. The synbiotic treatment consisted of 10 grams of Raftilose Synergy 1 and probiotic bacteria in capsule form, which was administered each day for 12 weeks. The results showed several biomarkers for colon cancer risk were positively modulated by the synbiotic treatment. The volunteers in the trial’s synbiotic group showed significantlydecreased genotoxic damage, that is damage to the cells’ DNA, compared with those who consumed the placebo. The results suggest that the consumption of this synbiotic composition may provide protectio against colorectal cancer.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters